Retrophin Bolsters Portfolio With Orphan Technologies Buyout

 
• By Joseph Haas

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Black Swan Event (face masks). Concept. A rare and unexpected event that has a major effect, such as a financial crash or pandemic. It is a metaphor often used in science or economics.
Deal adds to Retrophin's rare diseases pipeline

More from Deals

More from Business